The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement…
Q1 GAAP revenue of $106.2 million increased 333.5% year-over-year, driven by recently closed M&A transactions Moves to 4th largest cannabis…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc.…
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient…
LAFAYETTE, LA / ACCESS Newswire / May 5, 2026 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national…
VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage…
First quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025Dupixent® global net sales (recorded by Sanofi) increased…
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the first quarter ended March 31,…
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April…
This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from…